Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

1. A compound selected from the group consisting of:

2-(methylamino)-2-oxoethyl {2-[(4-chlorophenyl)oxy]ethyl}carbamate;

2-amino-2-oxoethyl (2-[(4-cyanophenyl)oxy]ethyl)carbamate;

2-amino-2-oxoethyl[4-(1-naphthalenyloxy]butyl]carbamate;

2-(methylamino)-2-oxoethyl 4-[(4′-fluoro-4-biphenyl)oxy]-1-piperidinecarboxylate;

2-(methylamino)-2-oxoethyl 4-{[(4-bromophenyl)-oxy]methyl}-1-piperidinecarboxylate;

2-(methylamino)-2-oxoethyl 4-{[(4′-(trifluoromethyl)-4-biphenyl)oxy]methyl}-1-piperidinecarboxylate;

2-amino-2-oxoethyl 4-[(1-naphthalenyloxy)methyl]-1-piperidinecarboxylate;

2-amino-2-oxoethyl 4-[(7-quinolinyloxy)methyl]-1-piperidinecarboxylate;

2-(methylamino)-2-oxoethyl 4-{2-[(4-bromophenyl)oxy]ethyl}-1-piperidinecarboxylate;

2-(methylamino)-2-oxoethyl 4-{2-[(4′-chloro-4-biphenyl)oxy]ethyl}-1-piperidinecarboxylate;

2-amino-2-oxoethyl 4-[2-(7-isoquinolinyloxy)-ethyl]-1-piperidinecarbamate; and

2-amino-2-oxoethyl 3-[(1-naphthalenyloxy)methyl]-1-pyrrolidinecarboxylate;

or a pharmaceutically acceptable salt thereof.

2. A method of treating a sleep disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein

m is 0, 1, 2 or 3;

n is 0, 1, 2 or 3;

X is oxygen, sulfur, SO or SO 2 ;

R 1 and R 2 are independently of one another hydrogen or C 1-3 alkyl; or

R 1 and R 2 together form a group —(CH 2 )—, where p represents an integer ranging from 1 to 5 such that n+p is an integer ranging from 2 to 5;

R 3 is hydrogen, fluorine, hydroxyl or methyl;

R 4 is a group of formula CHR 5 CONHR 6 ; wherein

R 5 is hydrogen or C 1-6 alkyl; and

R 6 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkylene; and

Y is selected from phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, thiazolyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, benzofuranyl, dihydrobenzofuranyl, benzothienyl, dihydrobenzothienyl, indolyl, isoindolyl, indolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzoxadiazolyl and benzothiadiazolyl; said Y is optionally substituted by one or more substituents Y 2 , which are identical to or different from one another, or by Y 3 ; wherein

Y 2 is halogen, cyano, nitro, C 1-8 alkyl, C 1-8 alkoxy, C 1-8 thioalkyl, C 1-8 fluoroalkyl,

C 1-8 fluoroalkoxy, C 1-8 fluorothioalkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy,

C 3-7 cycloalkyl-C 1-8 alkylene, C 3-7 cycloalkyl-C 1-8 alkyloxy, hydroxyl, NR 7 R 8 , NHCOR 7 , NHSO 2 R 7 , COR 7 , CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 , —O—(C 1-3 alkylene)-O—, phenyloxy, phenylthio, phenyl-C 1 -C 8 alkylene, phenyl-C 1 -C 8 alkyloxy or phenyl-C 1 -C 8 alkylthio group;

Y 3 is selected from phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; said Y 3 is optionally substituted by one or more substituents selected from Y 2 which are identical to or different from one another;

R 7 and R 8 are independently of one another hydrogen or C 1-6 alkyl; or

R 7 and R 8 with the nitrogen atom carrying them form an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine or piperazine ring optionally substituted by C 1-3 alkyl or benzyl;

with the proviso that, when R 1 and R 2 are independently of one another hydrogen or C 1-3 alkyl, m+n>1.

3. A pharmaceutical composition comprising at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable excipients.

4. A method of treating a sleep disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.